Halozyme宣布与GSK达成全球合作和许可协议，以开发多个有前景的肿瘤靶点的皮下制剂-动脉网

Halozyme Announces Global Collaboration and License Agreement with GSK to Develop Subcutaneous Formulations of Multiple Promising Oncology Targets

PR Newswire 等信源发布 2026-05-07 20:58



可切换为仅中文







Marks first ENHANZE

Marks首次ENHANZE

agreement

协议

to include

包含

ADC targets

ADC目标

Collaboration also includes option for additional future targets

合作还包括未来额外目标的选项

First clinical trial projected to initiate in 2026

首次临床试验预计于2026年启动

SAN DIEGO

圣地亚哥

，

May 7, 2026

2026年5月7日

/PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq:

/PRNewswire/ -- Halozyme Therapeutics, Inc.（纳斯达克：

HALO

光环

) ('Halozyme' or the 'Company') today announced the Company entered into a global collaboration and license agreement with GSK. Under the collaboration, GSK has licensed Halozyme's ENHANZE

）（'Halozyme'或'公司'）今天宣布公司与GSK达成了一项全球合作和许可协议。根据该合作协议，GSK已获得Halozyme的ENHANZE技术授权。

drug delivery technology for the development and potential commercialization of subcutaneous administration of multiple oncology targets, including antibody drug conjugates (ADCs), as well as an option for additional future drug targets.

用于开发和潜在商业化多个肿瘤靶点的皮下给药技术，包括抗体药物偶联物（ADCs），以及未来额外药物靶点的选择。

'We are excited to work with GSK to advance development of several oncology therapeutics. This agreement also marks our first collaboration on subcutaneous delivery of ADCs, where we believe subcutaneous delivery with ENHANZE may meaningfully improve the benefit–risk profile,' said Dr. Helen Torley, President and Chief Executive Officer of Halozyme.

“我们很高兴与GSK合作，推进多种肿瘤治疗药物的开发。该协议也标志着我们在ADC皮下递送方面的首次合作，我们相信通过ENHANZE进行皮下递送可能会显著改善效益-风险特征，”Halozyme总裁兼首席执行官Helen Torley博士表示。

'This collaboration reflects the continued recognition of ENHANZE as the gold standard for rapid, large-volume subcutaneous delivery, and underscores the value it provides to a growing number of leading pharmaceutical and biotechnology companies. Extending use of ENHANZE with ADCs represents a meaningful expansion of our potential addressable market, positions us at the forefront of a rapidly growing therapeutic class and reinforces the durability of our high-margin royalty revenue business.'.

“这次合作反映了ENHANZE作为快速、大容量皮下递送的黄金标准持续受到认可，并突显了它为越来越多领先的制药和生物技术公司提供的价值。将ENHANZE的使用扩展到ADC领域，标志着我们潜在可覆盖市场的有意义扩展，使我们处于这一快速增长的治疗类别前沿，并进一步巩固了我们高利润率特许权收入业务的持久性。”

'Novel approaches are required to reduce treatment burden for patients with cancer and help access easier forms of treatment,' said Eric Richards, SVP Head of Medicine Development Leaders Oncology, GSK. 'We see significant potential for subcutaneous formulations of several promising cancer targets, including ADCs, with ENHANZE and look forward to progressing the first clinical program.'.

“需要新的方法来减轻癌症患者的治疗负担，并帮助他们获得更便捷的治疗方式，”GSK肿瘤学医学开发负责人高级副总裁埃里克·理查兹表示。“我们看到多个有前景的癌症靶点（包括ADC）的皮下制剂与ENHANZE技术结合具有显著潜力，并期待推进首个临床项目。”

GSK will make an upfront payment to Halozyme and potential future milestone payments. Halozyme will also be entitled to royalties on net sales of products that incorporate ENHANZE

GSK将向Halozyme支付首付款，并可能支付未来的里程碑款项。Halozyme还将有权获得包含ENHANZE技术的产品的净销售额版税。

。

About Halozyme

关于Halozyme

Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE

Halozyme是一家生物制药公司，致力于推进颠覆性解决方案，以改善新兴和现有疗法的患者体验和治疗效果。作为ENHANZE技术的创新者

drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution facilitates the subcutaneous delivery of injected drugs and fluids, reducing treatment burden and improving convenience. ENHANZE

Halozyme的商业验证解决方案利用专有的rHuPH20酶药物递送技术，促进注射药物和液体的皮下递送，减轻治疗负担并提高便利性。ENHANZE

has touched more than one million patient lives through ten commercialized products across over 100 global markets and is licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen Pharmaceuticals, Merus N.V.

通过在全球100多个市场推出的十种商业化产品，已经惠及超过一百万名患者的生命，并已授权给包括罗氏、武田、辉瑞、杨森、艾伯维、礼来、百时美施贵宝、argenx、ViiV Healthcare、中外制药、Acumen Pharmaceuticals、Merus N.V.在内的领先制药和生物技术公司。

and Skye Bioscience..

和天际生物科学。。

Halozyme expanded its drug delivery technology portfolio to develop partner products using Hypercon™ and Surf Bio's hyperconcentration technology. Hypercon™ is an innovative microparticle technology expected to set a new standard in hyperconcentration of drugs and biologics by reducing injection volume for the same dosage and enabling administration in at‑home and healthcare‑provider settings.

Halozyme扩展了其药物递送技术组合，利用Hypercon™和Surf Bio的高浓缩技术开发合作伙伴产品。Hypercon™是一种创新的微粒技术，有望通过减少相同剂量下的注射体积，并实现家庭和医疗保健机构中的给药，为药物和生物制品的高浓缩树立新的标准。

The addition of Surf Bio's polymer‑based hyperconcentration technology further broadens the range of biologics that can be delivered subcutaneously, meaningfully expanding the scope of opportunities across therapeutic modalities. Together, Hypercon™ and Surf Bio's technology complement ENHANZE.

Surf Bio的基于聚合物的高浓度技术的加入进一步拓宽了可以皮下递送的生物制剂的范围，大幅扩展了跨治疗模式的机会范围。Hypercon™ 和 Surf Bio的技术相辅相成，与ENHANZE形成互补。

by enabling creation and delivery of highly concentrated biologics. The Hypercon™ technology has been licensed to leading biopharmaceutical partners, including Janssen, Eli Lilly, argenx, Vertex Pharmaceuticals and Oruka Therapeutics.

通过实现高浓度生物制剂的创造和递送。Hypercon™ 技术已授权给领先的生物制药合作伙伴，包括杨森、礼来、argenx、Vertex Pharmaceuticals 和 Oruka Therapeutics。

Halozyme also develops, manufactures and commercializes drug-device combination products using advanced auto-injector technologies designed to improve convenience, reliability and tolerability, enhancing patient comfort and adherence. The Company has two proprietary commercial products, Hylenex

Halozyme还利用先进的自动注射器技术开发、生产和商业化药物-设备组合产品，旨在提高便利性、可靠性和耐受性，增强患者的舒适度和依从性。该公司拥有两种专有的商业产品，Hylenex。

and XYOSTED

并且 XYOSTED

, partnered commercial products and ongoing development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc.

，与梯瓦制药和迈克德莫特实验室有限公司（隶属于维亚特里斯公司）合作的商业产品及持续开发项目。

Halozyme is headquartered in San Diego, CA, with offices in Ewing, NJ; Minnetonka, MN; and Boston, MA. Minnetonka is also the site of its operations facility.

Halozyme总部位于加利福尼亚州圣地亚哥，在新泽西州尤因、明尼苏达州明尼通卡和马萨诸塞州波士顿设有办事处。明尼通卡也是其运营设施的所在地。

For more information, visit

欲了解更多信息，请访问

www.halozyme.com

and connect with us on LinkedIn.

并在LinkedIn上与我们联系。

Forward Looking Statements

前瞻性声明

In addition to historical information, the statements set forth above include forward-looking statements including, without limitation, statements concerning royalty revenue growth, margins and durability, potential new partnerships and innovations, the possible activity, benefits and attributes of ENHANZE.

上述声明除包含历史信息外，还包括前瞻性陈述，包括但不限于有关特许权收入增长、利润率和持久性、潜在的新合作伙伴关系和创新、ENHANZE的可能活动、益处和属性的陈述。

, the possible method of action of ENHANZE

，ENHANZE 的可能作用方法

, its potential application to aid in the dispersion and absorption of other injected therapeutic drugs and statements concerning certain other potential benefits of ENHANZE

，其在帮助其他注射治疗药物的分散和吸收方面的潜在应用，以及关于ENHANZE某些其他潜在益处的陈述

including facilitating more rapid delivery and administration of larger volumes of injectable medications through subcutaneous delivery and potentially lowering the treatment burden, easing treatment access and improving the treatment experience for patients. These forward-looking statements also include statements regarding the product development and commercialization efforts of GSK (including the potential advancement and timing of the initiation of the clinical program, regulatory approval and launch as a result of such efforts and the potential future market opportunity for such products) and Halozyme's potential receipt of payments associated with achievement of certain milestones, and royalties on sales of commercialized products.

包括通过皮下递送更快速地输送和管理更大体积的注射药物，从而潜在降低治疗负担、简化治疗获取途径并改善患者的治疗体验。这些前瞻性声明还包括关于GSK产品开发和商业化的努力（包括可能推进和启动临床计划的时间、因这些努力而获得监管批准和上市的前景以及此类产品的未来市场机会）以及Halozyme因实现某些里程碑而可能收到的款项和商业化产品销售的特许权使用费相关的声明。

These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are typically, but not always, identified through use of the words 'expect,' 'believe,' 'enable,' 'may,' 'will,' 'could,' 'intends,' 'estimate,' 'anticipate,' 'plan,' 'predict,' 'probable,' 'potential,' 'possible,' 'should,' 'continue' and other words of similar meaning.

这些前瞻性陈述涉及风险和不确定性，可能导致实际结果与前瞻性陈述中的结果存在重大差异。前瞻性陈述通常（但并非总是）通过使用“预期”、“相信”、“促成”、“可能”、“将”、“能够”、“意图”、“估计”、“预期”、“计划”、“预测”、“很可能”、“潜在”、“可能”、“应该”、“继续”等类似含义的词语来识别。

Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including risks and uncertainties concerning whether development, regulatory and sales-based milestones will be achieved, uncertainties concerning whether collaborative products are ultimately developed, approved or commercialized and the potential future market for such products, unexpected levels of revenue growth, expenditures and costs, unexpected results or delays in development and regulatory review, unexpected regulatory approval requiremen.

实际结果可能与前瞻性声明中包含的预期存在重大差异，这是由于多种因素造成的，包括与是否能够实现开发、监管和销售相关的里程碑有关的风险和不确定性，围绕合作产品是否最终能够被开发、批准或商业化以及此类产品的潜在未来市场的不确定性，收入增长、支出和成本的意外水平，开发和监管审查过程中出现的意外结果或延迟，以及意外的监管审批要求。

Contacts:

联系人：

Tram Bui

电车贝儿

VP, Investor Relations and Corporate Communications

副总裁，投资者关系和企业传播

609-333-7668

[email protected]

电子邮件地址

Sydney Charlton

悉尼·查尔顿

Teneo